Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jochen K. Lennerz"'
Publikováno v:
The Journal of Molecular Diagnostics : JMD
The coronavirus disease 2019 (COVID-19) response necessitated innovations and a series of regulatory deviations that also affected laboratory-developed tests (LDTs). To examine real-world consequences and specify regulatory paradigm shifts, legislati
Autor:
Neal I. Lindeman, David Szeto, Allison MacLeay, Diane G. Brackett, Elizabeth P. Garcia, Long P. Le, Danielle K. Manning, Valentina Nardi, Jochen K. Lennerz, Ryan P. Frazier, Annette S. Kim, Christopher J. Gibson, R. Coleman Lindsley, Phani K. Davineni, Harrison Tsai
Publikováno v:
The Journal of Molecular Diagnostics : JMD
Assessment of internal tandem duplications in FLT3 (FLT3-ITDs) and their allelic ratio (AR) is recommended by clinical guidelines for diagnostic workup of acute myeloid leukemia and traditionally performed through capillary electrophoresis (CE). Alth
Autor:
Enrique Dominguez Meneses, Allison MacLeay, Aymen Baig, Ryan P. Frazier, Ju Cheng, Priscilla K. Brastianos, Jochen K. Lennerz, Maciej Pacula, Krista Hu, Hayley Robinson, Jesse Lee, Julie M. Batten, Rebecca S. Heist, A. John Iafrate, Aditya Bardia, Long P. Le, Yi Cao
Publikováno v:
The Journal of molecular diagnostics : JMD. 21(4)
The use of liquid biopsies to identify driver mutations in patients with solid tumors holds great promise for performing targeted therapy selection, monitoring disease progression, and detecting treatment resistance mechanisms. We describe herein the
Autor:
Julie M. Batten, Jason M. Baron, Stephen Black-Schaffer, Manish Gala, Kathryn J. Swoboda, David A. Sweetser, Heather M. McLaughlin, David A. Rasmussen, Long P. Le, Harland S. Winter, Nancy Berners-Lee, Anne Klibanski, Scott T. Weiss, William M. Hynes, Maciej Pacula, Marianne Boswell, Jeremy D. Schmahmann, Albrecht Stenzinger, David N. Louis, Meini Sumbada Shin, Jochen K. Lennerz, Jeffrey A. Golden, Heidi L. Rehm, A. John Iafrate
Publikováno v:
The Journal of molecular diagnostics : JMD. 18(5)
Next-generation sequencing has evolved technically and economically into the method of choice for interrogating the genome in cancer and inherited disorders. The introduction of procedural code sets for whole-exome and genome sequencing is a mileston